Highlights

• Syntara shares rose 4.35% to AUD 0.024 during the morning session on 6 July 2026 after the company released preliminary Phase 2 data for SNT-4728.

• The study showed a statistically significant reduction in brain inflammation unilaterally in the putamen, with a p-value of 0.0145.

• Out of 30 patients receiving active treatment, 20 recorded a reduction from baseline in the putamen region.

• The trial enrolled 41 patients with isolated REM Sleep Behaviour Disorder, a condition associated with elevated risk of progression to Parkinson’s and related diseases.

• Full clinical, imaging, digital and biological marker results are expected toward the end of Q3 2026.

Shares of Syntara Ltd (ASX:SNT) rose 4.35% to AUD 0.024 during the morning session on 6 July 2026 after the clinical-stage drug development company released preliminary analysis from its Phase 2 study of SNT-4728 in patients with isolated REM Sleep Behaviour Disorder, also known as iRBD. Although the stock remains down 52.00% over the past year, today’s move followed an update that showed early signs of reduced brain inflammation in a region linked to Parkinson’s Disease symptoms.

Early Trial Data Draws Investor Attention

Syntara reported preliminary results from the first tranche of data from its randomised, double-blind, placebo-controlled Phase 2 clinical trial of SNT-4728.

The study is notable because it is the first interventional trial designed to directly target neuroinflammation in patients with iRBD while also examining disease biology linked to possible progression toward Parkinson’s Disease.

SNT-4728 is being assessed as a first-in-class neuro-targeted anti-inflammatory therapy. The trial enrolled 41 patients and used a 3:1 randomisation structure, with 30 patients receiving active treatment.

The most closely watched early finding was a statistically significant reduction in brain inflammation in the putamen on one side of the brain. The company reported a p-value of 0.0145, with 20 of the 30 patients on SNT-4728 showing a reduction from baseline.

Why The Putamen Finding Matters

The putamen is an important brain region because it is associated with the hallmark motor symptoms of Parkinson’s Disease, including bradykinesia, rigidity and tremor.

Syntara also noted that the putamen has links to non-motor features, including impaired motivation.

The company said no statistically significant change in inflammation was detected in other predefined regions of interest, including the substantia nigra, caudate and occipital cortex.

However, broader imaging analyses identified further areas of statistically significant reduced TSPO signalling, including regions within the temporal lobe.

The trial used Positron Emission Tomography imaging with the Translocator Protein, known as TSPO, to monitor microglia activation and assess markers of neuroinflammation in the brain.

Expert Commentary Supports The Significance Of Early Findings

Professor Simon Lewis, Director of the Parkinson’s Disease Research Clinic at Macquarie University, said the result was notable given the study population.

He explained that SNT-4728 is being evaluated in a prodromal Parkinson’s population, where progression to symptomatic disease is usually slow and may take more than a decade.

Against that backdrop, he said observing a measurable change after only three months of treatment was encouraging, particularly given the statistically significant reduction in TSPO signal in the putamen.

Professor Lewis also said further imaging and biomarker analyses will be important in understanding the durability and clinical relevance of the observed effect.

Dr Lynsey Bilsland, Managing Director of Parkinson’s Research Ventures, said there is currently no drug that can stop or slow Parkinson’s progression. She said the trial suggests SNT-4728 may be able to modify a key process linked to Parkinson’s progression through short-term treatment before Parkinson’s is diagnosed.

Study Population Indicates High-Risk iRBD Group

Syntara said the trial successfully recruited an enriched iRBD population considered at elevated risk of phenoconversion to Parkinson’s and related diseases.

The median patient age was 68 years. Of the 41 enrolled patients, 38 were male, representing 93% of the trial population.

The company reported that 37 patients, or 90%, were hyposmic or anosmic, meaning they had reduced or lost sense of smell.

A further 19 patients, representing 46%, had low colour discrimination.

In addition, 39 patients, or 95%, had misfolded alpha-synuclein detected in cerebrospinal fluid, which supported the recruitment of a high-risk patient group.

Safety Profile Remains Favourable In Preliminary Analysis

The study used a once-daily oral dose of 15 mg of SNT-4728.

Dose selection was supported by prior clinical studies completed by Boehringer Ingelheim, which confirmed that the compound crosses the blood-brain barrier.

Syntara said the 15 mg dose is predicted to provide target engagement for both SSAO and MAO-B enzymes in the brain, supporting the intended reduction of brain inflammation.

The company also reported that SNT-4728 was safe and well tolerated in the study, consistent with the safety profile observed in earlier Phase 2 studies.

No treatment-related serious adverse events were reported. Across treatment arms, all adverse events were mild or moderate in severity.

Full Results Expected In Q3 2026

Syntara said additional results from the study are expected toward the end of Q3 2026.

The remaining data will include full clinical and imaging datasets, along with digital and biological markers.

The company said the complete dataset will help inform conclusions from the exploratory study and support assessment of the next development pathway for SNT-4728 in iRBD and potential slowing of progression to Parkinson’s in this patient population.

Based on emerging evidence of activity for SNT-4728 as a neuro-targeted anti-inflammatory therapy in iRBD, Syntara has also filed a new provisional patent application.

Investor Webinar Scheduled For Today

Syntara will host an investor webinar at 1:30pm AEST on Monday, 6 July 2026.

Chief Executive Officer Gary Phillips will discuss the preliminary SNT-4728 analysis alongside Chief Medical Officer Jana Baskar and principal investigator Professor Simon Lewis.

The company said a recording will be made available after the live session through the webinar link, Syntara’s website and its social media channels.

About Syntara

Syntara is a clinical-stage drug development company focused on extracellular matrix dysfunction, amine oxidase chemistry and related technologies.

The company is developing medicines for blood cancers and conditions linked to inflammation and fibrosis.

Its lead candidate, amsulostat, also known as SNT-5505 and previously PXS-5505, is being developed for myelofibrosis, a bone marrow cancer that causes scar tissue build-up and affects red blood cells, white blood cells and platelets.

Amsulostat has received Fast Track Designation, FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. It has completed a Phase 2a study in myelofibrosis as monotherapy and in combination with a JAK inhibitor.

Syntara has also initiated two Phase 1c/2 studies of amsulostat in patients with myelodysplastic syndrome.

Beyond blood cancer programs, Syntara is advancing topical pan-LOX inhibitors, including SNT-9465 in a Phase 1a/b study for hypertrophic scars and SNT-6302 in keloid scars through a collaboration with Professor Fiona Wood and the University of Western Australia.

The company is also studying SNT-4728 in collaboration with Parkinson’s UK as an SSAO/MAO-B inhibitor designed to treat sleep disorders and potentially slow progression of neurodegenerative diseases such as Parkinson’s by reducing neuroinflammation.

Syntara previously developed two respiratory products, Bronchitol for cystic fibrosis and Aridol, a lung function test, which were sold in October 2023.

What This Means For Investors

Syntara’s latest update provides early clinical evidence that SNT-4728 may be influencing neuroinflammatory pathways in iRBD patients, a group considered at elevated risk of progression to Parkinson’s and related diseases. The statistically significant reduction in inflammation in the putamen, alongside a favourable safety profile and no treatment-related serious adverse events, gives investors a new data point to assess. However, the company has indicated that full clinical, imaging, digital and biological marker results are still pending and are expected toward the end of Q3 2026.